Amiflamine

File:Amiflamine.png

Amiflamine

Amiflamine is a monoamine oxidase inhibitor (MAOI) that was developed in the 1970s by the pharmaceutical industry for the treatment of depression. It is a selective inhibitor of monoamine oxidase A (MAO-A), a type of enzyme that metabolizes monoamines such as serotonin, norepinephrine, and dopamine in the brain.

Pharmacology

Amiflamine acts by inhibiting the activity of MAO-A, thereby increasing the levels of monoamines in the brain. This results in an antidepressant effect. Unlike other MAOIs, amiflamine is selective for MAO-A, meaning it does not inhibit the activity of monoamine oxidase B (MAO-B), which metabolizes other types of monoamines. This selectivity is believed to reduce the risk of certain side effects associated with non-selective MAOIs, such as hypertensive crisis caused by the ingestion of foods containing tyramine.

Clinical Use

Amiflamine was developed for the treatment of depression, but it has not been widely used in clinical practice. This is partly due to the development of newer antidepressants that are easier to use and have fewer side effects. However, amiflamine may still be used in cases where other treatments have failed or are not tolerated.

Side Effects

The side effects of amiflamine are similar to those of other MAOIs. These can include nausea, dizziness, insomnia, and orthostatic hypotension. In rare cases, amiflamine can cause a hypertensive crisis if taken with certain foods or medications.

See Also

• Monoamine oxidase inhibitor
• Depression
• Serotonin
• Norepinephrine
• Dopamine

This article is a stub related to pharmacology. You can help WikiMD by expanding it!